Susquehanna International Group
ATOS icon

Susquehanna International Group’s Atossa Therapeutics ATOS Stock Holding History

Susquehanna International Group’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289K Buy
55,000
+52,433
+2,043% +$332K ﹤0.01% 10943
2025
Q4 		$22.7K Buy
2,567
+94
+4% +$1.19K ﹤0.01% 11930
2025
Q3 		$32.3K Buy
2,473
+86
+4% +$1.06K ﹤0.01% 11967
2025
Q2 		$29.7K Sell
2,387
-220
-8% -$2.63K ﹤0.01% 12253
2025
Q1 		$26.2K Sell
2,607
-2,240
-46% -$27.2K ﹤0.01% 12049
2024
Q4 		$68.3K Buy
4,847
+107
+2% +$2.09K ﹤0.01% 11548
2024
Q3 		$108K Buy
4,740
+1,207
+34% +$24.4K ﹤0.01% 11009
2024
Q2 		$63.1K Buy
3,533
+1,766
+100% +$39.1K ﹤0.01% 11309
2024
Q1 		$47.7K Buy
+1,767
New +$28.4K ﹤0.01% 11580
2023
Q4 		– Sell
-2,127
Closed -$23.6K – 12313
2023
Q3 		$23.6K Buy
+2,127
New +$30.9K ﹤0.01% 11561
2023
Q2 		– Sell
-1,287
Closed -$13.9K – 12026
2023
Q1 		$13.9K Sell
1,287
-440
-25% -$4.91K ﹤0.01% 12140
2022
Q4 		$13.7K Sell
1,727
-8,820
-84% -$101K ﹤0.01% 11867
2022
Q3 		$131K Sell
10,547
-2,400
-19% -$34.9K ﹤0.01% 11414
2022
Q2 		$212K Sell
12,947
-5,160
-28% -$81.3K ﹤0.01% 10486
2022
Q1 		$340K Sell
18,107
-10,726
-37% -$218K ﹤0.01% 9966
2021
Q4 		$692K Sell
28,833
-28,367
-50% -$1.04M ﹤0.01% 8295
2021
Q3 		$2.8M Sell
57,200
-157,300
-73% -$9.15M ﹤0.01% 5097
2021
Q2 		$20.3M Buy
214,500
+186,507
+666% +$9.87M ﹤0.01% 2007
2021
Q1 		$886K Buy
27,993
+26,513
+1,791% +$969K ﹤0.01% 8043
2020
Q4 		$21K Buy
+1,480
New +$34.3K ﹤0.01% 10878

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group's ATOS Position: Q1 2026 in Review

Susquehanna International Group sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 38,839 shares — an estimated $246K sold.

Susquehanna International Group first reported a position in ATOS in Q1 2018 and held it in 23 quarters. The position peaked at $16.4M in Q2 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Susquehanna International Group reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 38,839 Atossa Therapeutics shares in Q1 2026, an estimated $246K.
  • Susquehanna International Group first reported a position in Atossa Therapeutics in Q1 2018 and held it in 23 quarters.
  • Susquehanna International Group's Atossa Therapeutics position peaked at $16.4M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.